[go: up one dir, main page]

EP3377085A4 - Peptides and methods of treating endometriosis using the same - Google Patents

Peptides and methods of treating endometriosis using the same Download PDF

Info

Publication number
EP3377085A4
EP3377085A4 EP16862963.2A EP16862963A EP3377085A4 EP 3377085 A4 EP3377085 A4 EP 3377085A4 EP 16862963 A EP16862963 A EP 16862963A EP 3377085 A4 EP3377085 A4 EP 3377085A4
Authority
EP
European Patent Office
Prior art keywords
peptides
methods
same
treating endometriosis
endometriosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16862963.2A
Other languages
German (de)
French (fr)
Other versions
EP3377085A1 (en
Inventor
Eytan R. Barnea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioIncept LLC
Original Assignee
BioIncept LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/058877 external-priority patent/WO2016073513A1/en
Application filed by BioIncept LLC filed Critical BioIncept LLC
Publication of EP3377085A1 publication Critical patent/EP3377085A1/en
Publication of EP3377085A4 publication Critical patent/EP3377085A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/202IL-3
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/364Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP16862963.2A 2015-11-03 2016-11-03 Peptides and methods of treating endometriosis using the same Withdrawn EP3377085A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2015/058877 WO2016073513A1 (en) 2014-11-03 2015-11-03 Pif binding as a marker for immune dysregulation
US201662317628P 2016-04-03 2016-04-03
PCT/US2016/060319 WO2017079430A1 (en) 2015-11-03 2016-11-03 Peptides and methods of treating endometriosis using the same

Publications (2)

Publication Number Publication Date
EP3377085A1 EP3377085A1 (en) 2018-09-26
EP3377085A4 true EP3377085A4 (en) 2019-07-17

Family

ID=58663080

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16862963.2A Withdrawn EP3377085A4 (en) 2015-11-03 2016-11-03 Peptides and methods of treating endometriosis using the same

Country Status (5)

Country Link
EP (1) EP3377085A4 (en)
AU (1) AU2016349358B2 (en)
CA (1) CA3004055A1 (en)
IL (1) IL259096A (en)
WO (1) WO2017079430A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3341739A4 (en) 2015-08-28 2019-07-10 BioIncept LLC Mutant peptides and methods of treating subjects using the same
AU2016317574A1 (en) 2015-08-28 2018-03-29 Bioincept, Llc Compositions and methods for the treatment of neurodamage
US20200246424A1 (en) * 2017-07-17 2020-08-06 Bioincept, Llc Peptides and methods of transplantation and restorative organ function
WO2020106995A1 (en) * 2018-11-21 2020-05-28 Endomet Biosciences, Inc. Compositions and methods for treating endometriosis
CN113845582B (en) * 2021-10-15 2022-05-27 南京市妇幼保健院 Application of endogenous polypeptide in preparation of targeted drug for preventing or treating endometrial cancer
EP4248985A1 (en) * 2022-03-25 2023-09-27 Consejo Superior de Investigaciones Científicas (CSIC) Peptides for the treatment of retinitis pigmentosa

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201118A2 (en) * 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646003A (en) * 1994-03-23 1997-07-08 Barnea; Eytan R. Preimplantation factor
AU4233500A (en) * 1999-04-16 2000-11-02 Bioincept, Inc. Identification of a serum marker for endometriosis
US7723290B2 (en) * 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US7723289B2 (en) * 2003-10-22 2010-05-25 Bioincept, Llc PIF tetrapeptides
EP2970496B1 (en) * 2013-03-12 2018-07-18 Institute of Arthritis Research LLC Immunologically active polypeptide
EP3215847A4 (en) * 2014-11-03 2018-02-14 Bioincept LLC Pif binding as a marker for immune dysregulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201118A2 (en) * 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARCO SBRACIA ET AL: "PreImplantation Factor in endometriosis: A potential role in inducing immune privilege for ectopic endometrium", PLOS ONE, vol. 12, no. 9, 13 September 2017 (2017-09-13), pages e0184399, XP055439008, DOI: 10.1371/journal.pone.0184399 *
See also references of WO2017079430A1 *

Also Published As

Publication number Publication date
EP3377085A1 (en) 2018-09-26
AU2016349358B2 (en) 2019-12-05
IL259096A (en) 2018-06-28
AU2016349358A1 (en) 2018-06-14
WO2017079430A1 (en) 2017-05-11
CA3004055A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
IL276515B2 (en) Pd-l1-specific antibodies and methods of using the same
EP3270917A4 (en) Compounds and methods for the enhanced degradation of targeted proteins
EP3157471A4 (en) Exoskeleton and method of using the same
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
EP3145523A4 (en) Ras inhibitory peptides and uses thereof
EP3285805A4 (en) Therapeutic antibodies and uses thereof
EP3394098A4 (en) Anti-myostatin antibodies and methods of use
EP3274472A4 (en) Antimicrobial peptides and methods of use thereof
EP3215172A4 (en) Modifications and uses of conotoxin peptides
IL259096A (en) Peptides and methods of treating endometriosis using the same
EP3288379A4 (en) Peptide compositions and methods of use
EP3245272A4 (en) Novel proppant and methods of using the same
EP3313427A4 (en) Therapeutic peptides and methods of use thereof
EP3220908A4 (en) Compositions and methods for treating endometriosis
EP3334730A4 (en) Pyrrolomycins and methods of using the same
ZA201901942B (en) Nnif and nnif-related peptides and related methods
EP3270985A4 (en) Polypeptide compositions and methods of using the same
EP3341739A4 (en) Mutant peptides and methods of treating subjects using the same
EP3399990A4 (en) Therapeutic compositions including peptides and uses thereof
EP3178838A4 (en) Koc1-derived peptide and vaccine including same
EP3325499A4 (en) Novel peptide and use thereof
EP3209697A4 (en) Fn14-binding proteins and uses thereof
EP3241022A4 (en) Methods for protein and peptide reduction
EP3166406A4 (en) Cytokine-chitosan bioconjugates and methods of using the same
SG11201610918RA (en) Peptides and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180604

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038000000

Ipc: G01N0033567000

A4 Supplementary search report drawn up and despatched

Effective date: 20190614

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20190607BHEP

Ipc: C07K 7/08 20060101ALI20190607BHEP

Ipc: G01N 33/564 20060101ALI20190607BHEP

Ipc: G01N 33/567 20060101AFI20190607BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221103

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230314